# A Study to Evaluate the Safety of KAND567, in Combination With Carboplatin Therapy, in Women With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

> **NCT06087289** · PHASE1,PHASE2 · COMPLETED · sponsor: **Novakand Pharma AB** · enrollment: 18 (actual)

## Conditions studied

- Epithelial Ovarian Cancer
- Fallopian Tube Cancer
- Peritoneal Cancer

## Interventions

- **DRUG:** KAND567
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT06087289
- **Lead sponsor:** Novakand Pharma AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-26
- **Primary completion:** 2025-04-03
- **Final completion:** 2025-04-03
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2025-06-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06087289

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06087289, "A Study to Evaluate the Safety of KAND567, in Combination With Carboplatin Therapy, in Women With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06087289. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*